Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review

Waldfogel, Julie M., Nesbit, Suzanne Amato, Dy, Sydney M., Sharma, Ritu, Zhang, Allen, Wilson, Lisa M., Bennett, Wendy L., Yeh, Hsin-Chieh, Chelladurai, Yohalakshmi, Feldman, Dorianne, Robinson, Karen A. · 2017 · Neurology

Abstract

OBJECTIVE: To systematically assess the effect of pharmacologic treatments of diabetic peripheral neuropathy (DPN) on pain and quality of life. METHODS: We searched PubMed and Cochrane Database of Systematic Reviews for systematic reviews from 2011 to October 12, 2015, and PubMed, Embase, and the Cochrane Central Register of Controlled Trials for primary studies from January 1, 2013, to May 24, 2016. We searched Clinicaltrials.gov on March 9, 2016. Two reviewers independently evaluated studies for eligibility, serially abstracted data, and independently evaluated risk of bias and graded strength of evidence (SOE). RESULTS: We updated a recently completed systematic review of 57 eligible studies with 24 additional published studies and 25 unpublished studies. For reducing neuropathy-related pain, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine (moderate SOE), the anticonvulsants pregabalin and oxcarbazepine (low SOE), the drug classes tricyclic antidepressants (low SOE) and atypical opioids (low SOE), and botulinum toxin (low SOE) were more effective than placebo. We could not draw conclusions about quality of life due to incomplete reporting. All studies were short-term (less than 6 months), and all effective drugs had more than 9% dropouts from adverse effects. CONCLUSIONS: For reducing pain, duloxetine and venlafaxine, pregabalin and oxcarbazepine, tricyclic antidepressants, atypical opioids, and botulinum toxin were more effective than placebo. However, quality of life was poorly reported, studies were short-term, drugs had substantial dropout rates, and opioids have significant risks. Future studies should evaluate longer-term outcomes, use methods and measures recommended by pain organizations, and assess patients' quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000003882

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 158

Metadata

Authors
Waldfogel, J. M., Nesbit, S. A., Dy, S. M., Sharma, R., Zhang, A., Wilson, L. M., Bennett, W. L., Yeh, H.-C., Chelladurai, Y., Feldman, D., & Robinson, K. A.
Venue
Neurology
Published
2017-05-16
Volume
88
Issue
20
Pages
1958-1967
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2599069999
Cited by
158
References
7
FWCI
13.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. https://app.cochat.ai/papers/10.1212/wnl.0000000000003882
The paper
Waldfogel, J. M., Nesbit, S. A., Dy, S. M., Sharma, R., Zhang, A., Wilson, L. M., Bennett, W. L., Yeh, H.-C., Chelladurai, Y., Feldman, D., & Robinson, K. A. (2017). Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. https://doi.org/10.1212/wnl.0000000000003882

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.